Takara Bio USA, Inc. and TeselaGen Biotechnology, Inc. release a powerful new primer tool for easy design of In‑Fusion Cloning experiments

The In-Fusion Cloning Primer Design Tool, powered by TeselaGen, generates primer sequences and vector maps

Mountain View and San Francisco, CA—January 24, 2017—Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the In-Fusion Cloning Primer Design Tool, powered by TeselaGen Biotechnology, Inc. software. In-Fusion Cloning, developed by TBUSA, is a unique method that seamlessly joins together linear fragments of DNA in a single, 15-minute reaction. The free, online primer design tool facilitates easy design and a smooth transition from planning to experimental work. It was developed with TeselaGen specifically to cater to the requirements of In-Fusion Cloning and to support the wide range of cloning applications available when using In-Fusion technology, including multi-fragment cloning, mutagenesis, and general cloning. As an expert in in silico DNA editing and design, TeselaGen was uniquely positioned to anticipate the complexities and nuances inherent in building this custom tool.

"In-Fusion technology is unique in its ability to provide scientists with a streamlined and efficient method to build any clone. Primer design is critical to PCR cloning success, and we developed this new tool to guide researchers through the process, step-by-step. With less time spent on experimental design and cloning, our customers can spend more time advancing their research," said Carol Lou, President of Takara Bio USA, Inc.

The In-Fusion Cloning Primer Design Tool responds in real time to user input and allows for easy visualization and planning of any In‑Fusion Cloning project. It provides a final vector map and custom primer sequences, enabling seamless transition from design to bench work. No signup or software download is required, and all submitted sequences are protected with end-to-end encryption. No user data is stored.

In-Fusion Cloning technology is flexible in kit format and cloning setup, and the primer design tool accommodates both of these aspects: The primer design function is compatible with vector linearization by inverse PCR or restriction digest, and with single- or multiple-insert cloning. Additionally, In-Fusion Cloning contains protocols that accommodate lyophilized or liquid reagents and a variety of methods for purification of the PCR-generated inserts.

Dr. Andrew Farmer, Vice President of Research and Development at TBUSA, commented that "Concurrent with the release of this new tool, we have taken the opportunity to optimize primer specifications to improve the success of multiple-insert cloning approximately five-fold. This means that researchers can screen fewer colonies to obtain the right clone."

Dr. Michael Fero, Chief Executive Officer at TeselaGen, said, "TeselaGen is a platform that automates and optimizes protocol generation for DNA building and editing. We are very excited to open our platform to TBUSA users via this primer design tool. Takara Bio kits and protocols, including Clontech brand In-Fusion Cloning kits, are known for very high quality and close attention to detail. This collaboration is a natural one for us since making cloning easy and repeatable is a primary focus for us at TeselaGen."

To learn more about the In-Fusion Cloning Primer Design Tool and how it simplifies and expedites primer design for all In-Fusion Cloning projects, please visit takarabio.com/In-Fusion-Cloning-Tools.

About Takara Bio USA, Inc.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science reagents under the Takara, Clontech, and Cellartis brands. Key products include SMART cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq, Takara LA Taq, Titanium, and Advantage enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART library construction kits; the innovative In-Fusion cloning system; Guide-it gene editing tools; Tet-based inducible gene expression systems; and Living Colors fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation, and function studies; protein expression and purification; gene editing, and stem cell studies; and plant and food research. For more information, visit takarabio.com.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin reagent, which is used as a world standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, Takara Bio aims to extend its reach around the world. More information is available at takara-bio.com.

About TeselaGen Biotechnology, Inc.

TeselaGen builds secure enterprise quality software platforms for designing, building and precision editing DNA, enabling the development of biologic medicines, sustainably sourced chemicals and improved agricultural products. TeselaGen is privately held and is based in the software hub of San Francisco, CA. The company has received early recognition in the form of four US National Science Foundation funding awards, a US Department of Energy funding award and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution technology for efficient rapid prototyping and editing of recombinant molecules. Follow TeselaGen on Facebook, Twitter, LinkedIn, and Google+, and learn more at teselagen.com.